from Outperform, cuts price target to $29 from $31
- Leerink cites growing competitive pressure from prostate artery embolization as a key driver of its rating change
- Firm also points to a less favorable near-term setup, contributing to its reduced price target on Procept
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.